Private label eye health supplements: claims, actives and formats
Screens, artificial light and ageing make eye health one of the most dynamic supplement segments. Authorised claims, actives, dosage forms: here is what you need to launch your vision formula, by the R&D team at Irati Production.
Contact us
- Four nutrients have an authorised EU vision claim: vitamin A, zinc, riboflavin and DHA.
- For DHA, the claim requires an intake of 250 mg per day.
- Lutein, zeaxanthin, bilberry and saffron have no authorised health claim to date.
- The vision category is dominated by capsules: pectin-based gummies help a brand stand out.
- Irati Production makes your vision formula as gummies, capsules or tablets in Saumur, France.
A market driven by screens and ageing
Screen time, artificial lighting and longer lives make vision an everyday wellbeing topic. Consumers look for simple daily formulas and brands that are transparent about what each serving contains.
Research keeps exploring new actives, including polyphenols and carotenoids. A study on the ageing eye published on 3 November 2026 shows this interest, but its results are preliminary and support no claim. A brand's message must rely on what EU law allows.
Authorised health claims for vision
Regulation (EC) 1924/2006 and the EU register of authorised claims allow a brand to state that a nutrient contributes to the maintenance of normal vision for:
- Vitamin A, from 15% of the nutrient reference values per serving.
- Riboflavin (vitamin B2), under the same conditions.
- Zinc, under the same conditions.
- DHA, with an intake of 250 mg per day, stated to the consumer.
Lutein, bilberry, saffron: where do they fit?
Lutein, zeaxanthin, bilberry extract and saffron are common in vision formulas. They have no authorised health claim: claims on botanicals are still awaiting EU assessment, and their use falls under a regulated transitional regime.
These actives can be part of a formula, but labelling and marketing must stay cautious. The vision claim then relies on vitamin A, zinc, riboflavin or DHA at a sufficient dose.
Gummies, capsules or tablets?
Capsules remain the most common format in this category: they accept oily extracts and higher doses. Tablets suit vitamin and mineral formulas well.
Pectin-based, gelatin-free gummies make the daily intake more enjoyable and help a brand stand out on a shelf full of capsules. They require suitable formulation, for example for DHA, whose 250 mg daily dose is often split across several gummies.
Your vision formula, made in France
Irati Production manufactures your food supplements and functional drinks, private label or custom, at its site in Saumur, France.
- Pectin-based, gelatin-free gummies
- Capsules in sizes 1, 0 and 00
- Tablets and powders
- Review of claims and labelling
- ISO 22000 and HACCP certified, FDA registered site
Our answers on eye health supplements
Which health claims can an eye health supplement use?
Four nutrients have an authorised EU claim: vitamin A, riboflavin and zinc contribute to the maintenance of normal vision, as does DHA at 250 mg per day.
Does lutein have an authorised claim?
No. Lutein and zeaxanthin have no authorised health claim to date. They can be part of a formula, but marketing must rely on nutrients that do have a claim.
Can an eye health supplement be made as gummies?
Yes. Irati Production makes pectin-based, gelatin-free gummies. The formula is adapted to the chosen actives, and some doses, such as DHA, are split across several gummies.
Which format should I choose for a vision formula?
Capsules accept oily extracts and higher doses, tablets suit vitamins and minerals, and gummies stand out for the pleasure of the intake. The choice depends on the actives and the target consumer.
Can Irati Production review the labelling of an eye health supplement?
Yes. Irati Production manufactures your food supplements in Saumur, France, and offers a claims and labelling review service before production.
The information in this article is general and does not constitute regulatory advice. Each formula undergoes a technical and regulatory feasibility study.